Core Viewpoint - Clearmind Medicine Inc. has announced the publication of six patents in Hong Kong, focusing on innovative combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds to address under-treated health issues [1][2][3] Group 1: Patent Publication and Innovations - The newly published patents protect formulations that combine PEA with MDMA, LSD, Ketamine, Ibogaine, Psilocybin, and DMT, aiming to enhance therapeutic potential and improve safety and tolerability for mental health and neurological conditions [2] - The company currently holds a total of nineteen patent families, which include 31 granted patents, and plans to seek additional patents as opportunities arise [5] Group 2: Company Strategy and Objectives - Clearmind is focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to tackle significant health problems, including alcohol use disorder [4] - The CEO emphasized the strategic combination of PEA with well-characterized psychedelics to build a robust pipeline of next-generation candidates aimed at addressing unmet needs in mental health [3]

Core Viewpoint - NeuroThera Labs Inc. has announced a collaboration with Clearmind Medicine Inc. to file a patent for an innovative combination therapy aimed at treating major depressive disorder (MDD) [1][3] Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders through collaborations and innovative combinations [4] - Clearmind Medicine Inc. is a clinical-stage pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for various health issues, including alcohol use disorder [5] Patent Filing and Therapy Details - Clearmind has filed a patent application in Hong Kong for a combination therapy that includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) sourced from NeuroThera [2][3] - The MEAI-PEA combination is positioned as a non-hallucinogenic neuroplastogen option for treating depression, which affects over 332 million people globally [3] Market Potential and Advantages - The anticipated mechanism of action for the MEAI-PEA therapy suggests it could offer a safer, more accessible, and affordable alternative to existing antidepressants, including SSRIs [3][8] - There is a growing demand for novel treatments for major depressive disorder, highlighting the potential market opportunity for this combination therapy [8]

Core Insights - Clearmind Medicine Inc. has filed a patent application for a novel combination therapy aimed at treating major depressive disorder (MDD), which is projected to be a significant market exceeding $25 billion by 2030 [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics to address major health issues, including MDD and alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, with 31 granted patents, and plans to pursue additional patents to enhance its intellectual property [5] Treatment Innovation - The new treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), developed in partnership with NeuroThera Labs Inc. [2] - This MEAI-PEA synergy is positioned as a safer and more accessible alternative to traditional antidepressants, potentially benefiting over 332 million people globally suffering from depression [3]

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]